Viro - viro - Ravimiamet

mcneil ab - nikotiin - ravimnärimiskumm - 4mg 30tk; 4mg 90tk; 4mg 210tk; 4mg 204tk; 4mg 96tk; 4mg 12tk; 4mg 24tk

Viro - viro - Ravimiamet

leo pharma a/s - kaltsipotriool+beetametasoon - geel - 50mcg+0,5mg 1g 60g 1tk; 50mcg+0,5mg 1g 80g 1tk; 50mcg+0,5mg 1g 80g 2tk; 50mcg+0,5mg 1g 15g 1tk

Viro - viro - Ravimiamet

sandoz pharmaceuticals d.d. - mometasoon - salv - 1mg 1g 10g 1tk; 1mg 1g 30g 1tk; 1mg 1g 20g 1tk; 1mg 1g 100g 1tk; 1mg 1g 60g 1tk

Viro - viro - Ravimiamet

teva b.v. - diklofenak - ravimplaaster - 140mg 5tk; 140mg 10tk

Viro - viro - Ravimiamet

leo pharma a/s - kaltsipotriool+beetametasoon - salv - 50mcg+0,5mg 1g 15g 1tk; 50mcg+0,5mg 1g 120g 1tk; 50mcg+0,5mg 1g 100g 1tk; 50mcg+0,5mg 1g 60g 1tk

Viro - viro - Ravimiamet

gedeon richter plc. - lidokaiin - intrauteriingeel - 42mg 1ml 10ml 1tk

Euroopan unioni - viro - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muud dermatoloogilised preparaadid - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Euroopan unioni - viro - EMA (European Medicines Agency)

glaxo group ltd - retapamuliin - impetigo; staphylococcal skin infections - antibiootikumid ja kemoterapeutikumid dermatoloogiliseks kasutamiseks - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. vt punkte 4. 4 ja 5. 1 oluline teave kliinilise tegevuse retapamulin vastu erinevad liigid staphylococcus aureus. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopan unioni - viro - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - kloormetiin - mycosis fungoides - antineoplastilised ained - ledaga on näidustatud paikseks raviks seenhaigused fungoides-tüüpi naha t-rakulise lümfoomi (mf-tüüpi nahavÄhk) täiskasvanud patsientidel.

Euroopan unioni - viro - EMA (European Medicines Agency)

leo pharma a/s - takroliimus - dermatiit, atoopiline - muud dermatoloogilised preparaadid - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. esinevad neli või enam korda aastas), kes on olnud esialgse vastuse maksimaalselt kuue nädala jooksul ravi kaks korda päevas takroliimus salvi (kahjustused eemaldatud, peaaegu kustutatud või kergelt kahjustatud).